Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- AAP +1.6%, (CFO Tom Okray has decided to leave the organization effective April 15; reaffirms 2018 guidance)
M&A news:
- WMT +1.0% (Wal-Mart could buy online pharmacy startup PillPack, according to reports)
Other news:
- CBS +1.6% (Reuters reporting that CBS proposal will be below Viacom's current market valuation)
- AZN +1.4% (FDA accepts Biologics License Application for moxetumomab pasudotox for the treatment of adult patients with hairy cell leukaemia who have received at least two prior lines of therapy)
- SBGI +1.3% (responded to a series of media reports attacking the Company's recent promotional announcement for its local news)
- GSK +0.9% (US FDA accepts Biologics license application for moxetumomab pasudotox in hairy cell leukaemia)
- AMGN +0.5% (receives EU approval for XGEVA)
Analyst comments:
- EXAS +3.1% (upgraded to Buy from Neutral at BTIG Research)
- X +2.6% (upgraded to Buy from Neutral at Citigroup)
- CGNX +2.3% (upgraded to Neutral from Underweight at JP Morgan)
- RHI +1.8% (upgraded to Overweight from Equal Weight at Barclays)
- NVDA +1.4% (added to US 1 List at BofA/Merrill)
- CLDR +1.3% (target raised to $26 at Needham ahead of earnings this afternoon)
- SLB +1.0% (upgraded to Buy from Hold at SunTrust)
- BHGE +1.0% (upgraded to Overweight from Neutral at Piper Jaffray)